Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2234 total matches.

Intravenous Diclofenac (Dyloject)

   
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015  (Issue 1484)
has been shown to reduce opioid use and the incidence of opioid-related adverse effects.1 Administration ...
The FDA has approved Dyloject (Hospira), an IV formulation of the NSAID diclofenac sodium, for use in adults. It can be administered alone for treatment of mild to moderate pain or in combination with opioid analgesics for moderate to severe pain. Dyloject is the first injectable formulation of diclofenac to become available in the US.
Med Lett Drugs Ther. 2015 Dec 21;57(1484):171-2 | Show Introduction Hide Introduction

Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
death receptor-1 (PD-1) blocking antibody nivolumab (Opdivo)1 and the anti-CLA-4 antibody ipilimumab ...
The FDA has approved the combined use of the programmed death receptor-1 (PD-1) blocking antibody nivolumab (Opdivo) and the anti-CLA-4 antibody ipilimumab (Yervoy) for treatment of BRAF V600 wild-type unresectable or metastatic melanoma. This is the first immunotherapy combination to be approved for treatment of any type of cancer.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):168 | Show Introduction Hide Introduction

Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third longacting human insulin ...
The FDA has approved insulin degludec (Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and insulin glargine (Lantus, Toujeo) were approved earlier.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):163-4 | Show Introduction Hide Introduction

Ferric Citrate (Auryxia) for Hyperphosphatemia

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
Exams Published by The Medical Letter, Inc. • A Nonprofit Organization Table 1. Some Oral Drugs ...
The FDA has approved ferric citrate (Auryxia – Keryx), an oral phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the second iron-based phosphate binder to be approved in the US, and the first that causes significant systemic absorption of iron. Auryxia is not FDA-approved for treatment of iron deficiency anemia.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):166-7 | Show Introduction Hide Introduction

Deoxycholic Acid (Kybella) for Double Chin

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
.1 Kybella contains synthetically derived deoxycholic acid. When the drug is injected ...
The FDA has approved the use of subcutaneous injections of deoxycholic acid (Kybella – Kythera/Allergan) to improve the appearance of moderate to severe convexity or fullness associated with submental fat (double chin) in adults. It is the first drug approved for this indication.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):165-6 | Show Introduction Hide Introduction

Idarucizumab (Praxbind) - An Antidote for Dabigatran

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
dabigatran etexilate (Pradaxa).1 Idarucizumab is the first specific reversal agent to become available ...
The FDA has approved idarucizumab (Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa). Idarucizumab is the first specific reversal agent to become available for one of the new oral anticoagulants.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):157-8 | Show Introduction Hide Introduction

Bexsero - A Second Serogroup B Meningococcal Vaccine

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
. It is the second serogroup B meningococcal vaccine to be approved in the US; Trumenba was the first.1 Both ...
The FDA has approved Bexsero (Novartis/GSK), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B. It is the second serogroup B meningococcal vaccine to be approved in the US; Trumenba was the first. Both vaccines are approved for use in persons 10-25 years old. Bexsero is approved in Europe, Canada, and Australia for use in children as young as 2 months old.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):158-9 | Show Introduction Hide Introduction

Tiotropium/Olodaterol (Stiolto Respimat) for COPD

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler, Spiriva Respimat)1 ...
The FDA has approved a fixed-dose, orally inhaled combination of the long-acting anticholinergic tiotropium and the long-acting beta2-adrenergic agonist olodaterol (Stiolto Respimat — Boehringer Ingelheim) for long-term, once-daily, maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD). It is not approved for treatment of acute exacerbations of COPD or for treatment of asthma. Tiotropium (Spiriva Handihaler, Spiriva Respimat) and olodaterol (Striverdi Respimat) are also available separately for once-daily treatment of...
Med Lett Drugs Ther. 2015 Nov 23;57(1482):161-2 | Show Introduction Hide Introduction

In Brief: Technivie for HCV Genotype 4 Infection (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
as Viekira Pak for treatment of HCV genotype 1 infection.1 HCV genotype 4 is uncommon in the US and Canada ...
The FDA has approved Technivie (Abbvie), a fixed-dose combination of the direct-acting antiviral agents ombitasvir and paritaprevir and the pharmacokinetic enhancer ritonavir, for oral treatment of chronic hepatitis C virus (HCV) genotype 4 infection in patients without cirrhosis. It is indicated for use in combination with ribavirin. Ombitasvir/paritaprevir/ritonavir copackaged with dasabuvir, an HCV RNA polymerase inhibitor that has little activity against HCV genotype 4, is approved as Viekira Pak for treatment of HCV genotype 1 infection.1HCV genotype 4 is uncommon in the US and Canada. It...
Med Lett Drugs Ther. 2015 Nov 23;57(1482):e162 | Show Introduction Hide Introduction

Cobicistat (Tybost) and Combinations for HIV

   
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015  (Issue 1482)
(Prezcobix — Janssen) for treatment of HIV-1 infection. Both atazanavir and darunavir have traditionally ...
Cobicistat, a pharmacokinetic enhancer that boosts levels of some HIV drugs but has no antiretroviral activity of its own, is now available alone as Tybost (Gilead) and in fixed-dose combinations with the protease inhibitors atazanavir (Evotaz — BMS) and darunavir (Prezcobix — Janssen) for treatment of HIV-1 infection. Both atazanavir and darunavir have traditionally been used in combination with the CYP3A inhibitor ritonavir (Norvir) to boost their serum concentrations, but neither is available in a fixed-dose combination with ritonavir.
Med Lett Drugs Ther. 2015 Nov 23;57(1482):159-60 | Show Introduction Hide Introduction